相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction
Pasquale Mone et al.
DIABETES CARE (2022)
Chronic Kidney Disease and Cognitive Impairment
Asam Murtaza et al.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2021)
2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction A Report of the American College of Cardiology Solution Set Oversight Committee
Thomas M. Maddox et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease Abstracts
[Anonymous]
KIDNEY INTERNATIONAL (2021)
Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes
Daisuke Yabe et al.
BMJ OPEN (2021)
Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis
Wen-Hsuan Tsai et al.
SCIENTIFIC REPORTS (2021)
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7% Results From the CREDENCE Trial
Christopher P. Cannon et al.
CIRCULATION (2020)
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
Erik J. M. van Bommel et al.
KIDNEY INTERNATIONAL (2020)
CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis
Eileen O'Meara et al.
CANADIAN JOURNAL OF CARDIOLOGY (2020)
Albuminuria and Estimated GFR as Risk Factors for Dementia in Midlife and Older Age: Findings From the ARIC Study
Johannes B. Scheppach et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors
Christopher S. Wilcox
HYPERTENSION (2020)
Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes
Carmen Hierro-Bujalance et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
Mechanisms of cognitive dysfunction in CKD
Davide Viggiano et al.
NATURE REVIEWS NEPHROLOGY (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy
Riobaldo Cintra et al.
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cognitive Impairment in CKD: Pathophysiology, Management, and Prevention
David A. Drew et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Associations of Chronic Kidney Disease Markers with Cognitive Function: A 12-Year Follow-Up Study
Julian W. Sacre et al.
JOURNAL OF ALZHEIMERS DISEASE (2019)
A Systematic Review of Cognitive Impairments Associated With Kidney Failure in Adults Before Natural Age-Related Changes
Julia Brodski et al.
JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Canagliflozin and Stroke in Type 2 Diabetes Mellitus Results From the Randomized CANVAS Program Trials
Zien Zhou et al.
STROKE (2019)
Mechanisms of Stroke in Patients with Chronic Kidney Disease
Shivani Ghoshal et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
Update on Diabetic Nephropathy: Core Curriculum 2018
Kausik Umanath et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2018)
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults
Lorraine Lipscombe et al.
CANADIAN JOURNAL OF DIABETES (2018)
SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A South Australian Clinical Case Series and Australian Spontaneous Adverse Event Notifications
Emily J. Meyer et al.
DIABETES CARE (2018)
Albuminuria and Microalbuminuria as Predictors of Cognitive Performance in a General Population: An 11-Year Follow-Up Study (vol 62, pg 635, 2018)
Laura L. Ekblad et al.
JOURNAL OF ALZHEIMERS DISEASE (2018)
Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors-overlooked and overwhelming? A retrospective case series
Nino Cristiano Chilelli et al.
ENDOCRINE (2018)
Albuminuria in Association with Cognitive Function and Dementia: A Systematic Review and Meta-Analysis
Marios K. Georgakis et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats
Piangkwan Sa-nguanmoo et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2017)
Estimated GFR, Albuminuria, and Cognitive Performance: The Maastricht Study
Remy J. H. Martens et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2017)
Forxiga (dapagliflozin): Plausible role in the treatment of diabetes-associated neurological disorders
Sibhghatulla Shaikh et al.
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY (2016)
Frailty and Cognitive Function in Incident Hemodialysis Patients
Mara A. McAdams-DeMarco et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes
Bruce Neal et al.
DIABETES CARE (2015)
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
Bowen Lin et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Invokana (Canagliflozin) as a Dual Inhibitor of Acetylcholinesterase and Sodium Glucose Co-Transporter 2: Advancement in Alzheimer's Disease-Diabetes Type 2 Linkage via an Enzoinformatics Study
Syed M. D. Rizvi et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2014)
Stroke and cerebrovascular diseases in patients with chronic kidney disease
Kazunori Toyoda et al.
LANCET NEUROLOGY (2014)
Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline
Paul E. Stevens et al.
ANNALS OF INTERNAL MEDICINE (2013)
Decline in renal functioning is associated with longitudinal decline in global cognitive functioning, abstract reasoning and verbal memory
Adam Davey et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2013)
Albuminuria and Decline in Cognitive Function The ONTARGET/TRANSCEND Studies
Joshua I. Barzilay et al.
ARCHIVES OF INTERNAL MEDICINE (2011)
Dementia and cognitive impairment in ESRD: diagnostic and therapeutic strategies
Manjula Kurella Tamura et al.
KIDNEY INTERNATIONAL (2011)
Chronic Kidney Disease and Cognitive Function in Older Adults: Findings from the Chronic Renal Insufficiency Cohort Cognitive Study
Kristine Yaffe et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2010)
Impact of Microalbuminuria on Incident Stroke A Meta-Analysis
Meng Lee et al.
STROKE (2010)
Low glomerular filtration rate and risk of stroke: meta-analysis
Meng Lee et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Test-retest reliable coefficients and 5-year change scores for the MMSE and 3MS
TN Tombaugh
ARCHIVES OF CLINICAL NEUROPSYCHOLOGY (2005)
The montreal cognitive assessment, MoCA:: A brief screening tool for mild cognitive impairment
ZS Nasreddine et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2005)
分享论文
